Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB) announced in a news release it partnered to provide its iUGO CARE remote patient monitoring (RPM) platform to a U.S. pharmacy network for use with its chronic disease patients.
The pharmacy network manages pharmacies in 10 states mostly along the East Coast and consists of 10,000 prescribing physicians who treat patients with chronic conditions including diabetes, congestive heart failure, chronic obstructive pulmonary disease and elevated blood pressure. Along with general services, the pharmacies provide specialized ones such as dispensing medications for long-term care, assisted living and skilled nursing facilities.
"Reliq's iUGO CARE platform can help empower and engage patients coping with chronic conditions at home or in residential care facilities, helping to improve their health with medication adherence tools and remote monitoring of key health metrics," Reliq CEO Lisa Crossley said in the release.
In other partnership news, announced in a separate news release, Reliq will provide to Smart Meter, a Florida-based diabetes management technology company, its iUGO CARE RPM and Chronic Care Management solutions for patients with diabetes and other chronic conditions.
For this relationship, Reliq will integrate its platform into Smart Meter's iGlucose diabetes management system. "Combining our iGlucose meter and cost effective test strips and Reliq's iUGO CARE platform to support caregiver workflows, automatically collect key patient health data and connect residents to physicians through virtual visits will create new revenue models for residential care, increase profits and enhance patient and family satisfaction," Smart Meter CEO Brahim Zabeli said in the release.
Also, Smart Meter, to garner additional clients, will obtain contract outreach and engagement services through Reliq's call center in Port St. Lucie, Fla. The center's purpose is to implement Reliq's RPM and CCM solutions with patients, physicians and payors.[NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Reliq Health Technologies. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of Reliq Health Technologies. Please click here for more information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Techologies, a company mentioned in this article.